Oncology

When treating patients with bone metastases, the biosimilar demonstrated equivalent safety and efficacy to its reference product.

A patient, who formerly had previously been treated with CAR therapy for multiple myeloma, achieved remission for both multiple myeloma and lymphoma.

The action follows phase 3 trial data that demonstrated reduced phlebotomy dependence, improved hematocrit control, and eased symptoms.

The study results could help bolster metformin as a potentially attractive option for patients with HER2-positive breast cancer.

Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.

A new study found that the natural alkaloids mitragynine and 7-hydroxymitragynine from Mitragyna speciosa showed stable binding and favorable drug-likeness as potential HER2 inhibitors in breast cancer.

Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.

Palbociclib revolutionizes HR+/HER2- breast cancer treatment, enhancing outcomes with endocrine therapies and promising new combinations for better patient care.

Research reveals that clinical stage significantly influences survival rates in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.

Both preclinical and translational evidence support MET inhibition as a therapeutic approach in patients with small cell lung cancer (SCLC).

Enfortumab vedotin is one of many effective antibody-drug conjugates on the market that can be utilized to improve the treatment of urothelial carcinoma.

New research reveals that immunoglobulin replacement therapy fails to lower infection-related hospitalizations in those with chronic lymphocytic leukemia (CLL), raising treatment concerns.

Precision oncology has shifted, yet pharmacists’ roles remain underutilized.

Precision medicine transforms cancer care, enhancing patient outcomes through targeted therapies, yet faces challenges in community access and biomarker testing.

Oncology pharmacists are increasingly shaping patient care.

New research highlights abemaciclib and ribociclib as promising treatments for early HR-positive, HER2-negative breast cancer, emphasizing survival benefits and adverse effects.

Combination therapy with tremelimumab and durvalumab significantly improves survival in patients with liver cancer compared with standard sorafenib treatment.

Many adults remain unaware of HPV's cancer risks, highlighting the urgent need for increased awareness.

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

Pharmacists optimize biosimilar and 505(b)(2) use through collaboration, education, and integration.

Acalabrutinib shows improved safety and survival rates in chronic lymphocytic leukemia (CLL), reducing risks of mortality and cardiovascular complications.

Oncology pharmacists can lead value-based care integration under EOM with data-driven strategies.

Elicio Therapeutics' ELI-002 2P cancer vaccine shows promising survival benefits in patients with pancreatic and colorectal cancer, enhancing immune responses.

TAR-200 shows promise in treating BCG-unresponsive bladder cancer, achieving 82% tumor elimination and offering new hope for patients.

New research links high perilipin 2 expression in lung adenocarcinoma to aggressive disease progression and shorter survival, highlighting potential treatment targets.

BV-R2 combination shows survival benefit across high-risk subgroups.

Natural compounds like Prunus armeniaca and bee venom enhance breast cancer treatment, boosting efficacy and reducing adverse effects.

Pharmacists play a crucial role in improving vaccination rates among patients with cancer, addressing barriers, and enhancing patient education in oncology care.

Oncology pharmacists could be canaries in the coal mine of health care systems.

Glofitamab-GemOx improves survival in transplant-ineligible patients with R/R DLBCL.